Format

Send to

Choose Destination
See comment in PubMed Commons below
Gynecol Oncol. 2009 Jun;113(3):384-90. doi: 10.1016/j.ygyno.2009.01.008. Epub 2009 Feb 20.

Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.

Author information

1
Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL 35249, USA. pfrederick5@hotmail.com

Abstract

OBJECTIVE:

To present an overview of selected monoclonal antibodies (mAbs) that have been studied in epithelial ovarian cancer with a focus on combination treatment with conventional chemotherapy.

METHODS:

The authors perform a narrative review of the literature. Preclinical studies that provided rationale for mAb use are examined, and selected clinical trials that evaluated efficacy and tolerability are reviewed.

RESULTS:

Numerous mAbs have been utilized in epithelial ovarian cancer, including bevacizumab (anti-vascular endothelial growth factor), trastuzumab (anti-human epidermal growth factor-2), cetuximab (anti-epidermal growth factor receptor), and oregovomab (anti-CA125). Favorable preclinical results have lead to the development of a number of clinical trials. Side-effects have been minimal and combination therapy has been well-tolerated. Efficacy has been variable in the clinical trials.

CONCLUSIONS:

Targeted treatment with mAbs in conjunction with cytotoxic chemotherapy has been an important research area during the last decade. This therapeutic approach holds promise for improved outcomes in patients with ovarian cancer.

PMID:
19232697
DOI:
10.1016/j.ygyno.2009.01.008
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center